- Optimi Health (OPTI) has requested a final site inspection for its dealer’s license
- The Optimi team has built a world-class GMP capable facilities from the ground up
- Concurrent to the finalization of the dealer’s license submission it has now presented its analytical laboratory license for consideration and review
- Additional study capability includes potency, stability and identity testing utilizing thin layer chromatography, ultraviolet-visible spectroscopy, and mass spectrometry
- Optimi Health (OPTI) is down 3.85 per cent, trading at C$0.50 at 2:24 pm EST
Optimi Health Corp. (OPTI) has completed construction of its proposed dealer’s license facility in Princeton, B.C. and called for a final site inspection.
The Optimi team has endeavoured to build world-class GMP-capable facilities from the ground up. Since December of 2020, the company has been heavily invested in completing its state-of-the-art facilities in full compliance with Health Canada’s Directive on Physical Security Requirements for Controlled Substances.
As noted in the recently filed annual financials, as of September 30, 2021, $8,586,465 has been spent on the construction of these facilities.
Following its facility update on September 14, 2021, the schedule 8 security protocol is commissioned, Argus environmental control system is being installed, curbs and blacktop poured, interior clean walls are erect, HVAC units are mounted, and ancillary cultivation equipment has arrived on site.
Concurrent to the finalization of the dealer’s license submission, Optimi has presented its analytical laboratory license for consideration and review. Optimi believes a healthy domestic regulatory environment is a critical and necessary driver of the rigorous safety and security regulations for licensed producers and builds confidence in local production quality and capacity.
“Regulations are critical and necessary for building product safety and efficacy,” notes Company CSO Justin Kirkland.
It has recently completed the purchase of research and development as well as analytical instrumentation which is poised to dramatically ramp up in-house productivity.
Upon final approval by the onsite quality assurance team, Optimi will be able to provide assays to include potency testing by high-performance liquid chromatography including a diode array detector that allows for measuring multiple substances at multiple wavelengths (or components) simultaneously.
Additional study capability includes potency, stability and identity testing utilizing thin layer chromatography, ultraviolet-visible spectroscopy, and mass spectrometry.
The laboratory now provides an advanced ability to test for heavy metals and elemental impurities in compliance with guidelines put forth by the FDA, USP and ICH organizations to protect patients from the risks associated with heavy metal contaminants.
Michael Kydd, regulatory consultant to Optimi states, “The company is clearly focused on respecting the regulatory process and by so doing, is positioning itself as an undisputed global supply leader through the development of one of Canada’s highest-quality GMP-capable facilities.”
“The entire team looks forward to building strong relationships within national and international governments as the industry matures. In my opinion collaboration and communication define excellence, and the work we undertake today with Health Canada positions us to propel Optimi as an industry leader in standards and excellence around the world,” added Kydd.
Optimi Health CEO Bill Ciprick concludes, “I’m extremely proud of our recent and ongoing achievements. The senior leadership team has a strong history of operational and facility management in the cultivation of GMP-certified health products.”
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets.
Optimi Health (OPTI) is down 3.85 per cent, trading at C$0.50 at 2:24 pm EST.
